First-line anti-TNF agents, ustekinumab and vedolizumab perform similarly in Crohn’ disease, but not in ulcerative colitis
Our real-world data suggest similar drug persistence and efficacy of first-line treatments with anti-TNF agents, vedolizumab and ustekinumab in Crohn's disease. In ulcerative colitis, however, drug persistence was higher for vedolizumab compared to anti-TNF agents, but on the cost of lower PRO-2 remission rates.
Authors
- Gregor Novak (ORCID: https://orcid.org/0000-0002-9110-9188)
- David Drobne (ORCID: https://orcid.org/0000-0003-2734-675X)
- Borut Štabuc
- Damjan Manevski (ORCID: https://orcid.org/0000-0001-9044-2862)
- Jurij Hanžel (ORCID: https://orcid.org/0000-0003-3158-8014)
- Eva Supovec
Institutions
- University of Ljubljana (SI)
- Ljubljana University Medical Centre (SI)
Publication Details
- Journal
- European Journal of Gastroenterology & Hepatology
- Published
- 2025-02-06
- DOI
- https://doi.org/10.1097/meg.0000000000002940
- Citations
- 5
- Primary Topic
- Inflammatory Bowel Disease
- Type
- article
- Field-Weighted Citation Impact
- 9.09
Funders
- Javna Agencija za Raziskovalno Dejavnost RS